In patients with heart failure with reduced ejection fraction (HFrEF), consensus guidelines recommend rapid sequence initiation of available guideline-directed medical therapy (GDMT), including evidence-based beta-blockers, renin-angiotensin system inhibitors (RASi) or angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter 2 inhibitors (SGLT2).1 Here, NR3C2 is linked to heart failure.